Dr. Srinivasan is a translational biomedical an a formulation scientist with a distinguished academic and research career spanning the United Kingdom, Germany, the United States, and India. She holds an MSc in Biomedical Sciences and a PhD from the University of Bradford, UK, where she was awarded the University of Bradford International Scholarship for her master's degree and a National Health Service (NHS) Fellowship for her doctoral research. Her PhD focused on identifying clinical biomarkers for patients with liver and pancreatic diseases and cancer.

Prior to her postdoctoral training, Dr. Srinivasan gained research experience at the Max Planck Institute, Germany, investigating the role of Protein Kinase C (PKC) in cancer biology. She subsequently joined Thomas Jefferson University, Philadelphia, USA, as a postdoctoral researcher, where she conducted extensive work in cancer nanomedicine and the formulation of nanoparticles for targeted drug delivery — with a particular focus on lung and breast cancer. A highlight of this period was her pioneering research on delivering nano-sized monoclonal antibodies as nanoparticles targeting non-small cell lung cancer cell lines, validated in nude mouse models. This work resulted in a patent filing and earned her the prestigious American Association of Pharmaceutical Sciences (AAPS) Innovation in Biotechnology Award (May 2013), sponsored by Genentech, at the National Biotechnology Conference in San Diego, California.

As an independent researcher, Dr. Srinivasan's work is driven by a commitment to translating scientific discovery into real-world impact. Her research-to-commercialization model encompasses lab developed/ fabricated biomedical product development, targeted drug delivery formulations, pre-clinical screening and toxicology assessment, and pilot-phase clinical trials — reflecting her evolution from biomedical science graduate to full-spectrum translational scientist.

She has successfully secured competitive research funding from several prestigious bodies, including DBT-BIRAC-PACE, BIRAC-BIG, and Nidhi Prayas, in addition to industry consultancy projects. She has established spin-off companies to advance the commercial translation of her research. In recognition of her scientific standing, she was selected as a Scientific High-Level Visiting Fellow through the French Institute in India program, enabling collaborative research at a leading public institute in France. She is also a Fellow of the Indian National Science Academy (INSA). Dr. Srinivasan's career exemplifies the bridge between fundamental biomedical research and its practical application for patient benefit.